Monitor insider transaction filings for Poole's initial stock option and RSU grants, and assess any potential influence on corporate governance or audit oversight. No immediate trading impact expected.
ACAD drugs
ACAD drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 5 $22.40entry
- T+1 · 9mo ago −1.07%α +0.24% · $22.16
- T+5 · 8mo ago −5.04%α −2.81% · $21.27
- T+20 · 8mo ago −0.89%α +2.90% · $22.20
- T+60 · 6mo ago −3.93%α −15.23% · $21.52
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Acadia Pharmaceuticals appointed Jonathan M. Poole to its board of directors and the Audit Committee, effective March 3, 2026. Poole will receive cash retainers totaling $62,500 annually (prorated) and initial equity awards with a target fair value of $200,000, plus a prorated annual grant valued at $95,300.
Key Facts
- Jonathan M. Poole appointed to the Board of Directors and Audit Committee effective March 3, 2026
- Poole is a non-employee director serving as a Class II director with term expiring at the 2027 Annual Meeting
- He will receive annual cash retainers of $50,000 (Board) and $12,500 (Audit Committee), prorated and payable per policy
- Received initial equity grant with target fair value of $200,000, split equally between stock options and RSUs, vesting over three years
- Received prorated annual equity grant with target fair value of $95,300, split equally between options and RSUs, vesting over one year or by next annual meeting
- Starting at 2026 Annual Meeting, eligible for annual equity grants with target value of $400,000
Financial Impact
Approximately $357,800 in total initial compensation (cash and equity) for the appointment, with ongoing annual cash compensation of $62,500 and equity grants of $400,000
Risk Factors
- Potential dilution from new equity grants
- Limited immediate operational impact from board appointment
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-092213 |
| Document: 0001193125-26-092213-index-headers.html | 0001193125-26-092213 |
| Document: 0001193125-26-092213-index.html | 0001193125-26-092213 |
| Document: 0001193125-26-092213.txt | 0001193125-26-092213 |
Track record
14 reports on ACAD
1 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +5.01% at T+20 after the May 6, 2026 report. 2 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $18.28 Now $18.67 +2.13% settles Dec 9
- Nov 4, 202612d ago 8-K Bullish 6/10 Entry $21.24 Now $18.67 −12.10% settles Dec 4
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $20.57 Now $18.67 −9.24% settles Dec 2
- Oct 23, 202624d ago 8-K Neutral 3/10 Entry $19.74 Now $18.67 −5.42% settles Nov 23
- Sep 24, 20267w ago 8-K Bullish 6/10 Entry $20.68 to $19.73 Now $18.67 −9.72% ▼ −4.59% −3.12% vs SPY
- Sep 11, 20269w ago 8-K Neutral 3/10 Entry $27.52 to $19.41 Now $18.67 −32.16% ▼ −29.47% −31.73% vs SPY
- Aug 16, 202613w ago Institutional Cluster Mixed 5/10 Entry $29.01 to $26.76 Now $18.67 −35.64% ▼ −7.76% −5.78% vs SPY
- Aug 7, 202614w ago Insider Cluster Neutral 2/10 Entry $29.39 to $27.58 Now $18.67 −36.47% ▼ −6.16% −5.24% vs SPY
- Jun 11, 202622w ago Institutional Cluster Bearish 6/10 Entry $21.39 to $26.41 Now $18.67 +12.72% ▼ −23.47% −21.58% vs SPY
- May 6, 202627w ago 8-K Bearish 6/10 Entry $22.56 to $21.43 Now $18.67 +17.24% ▲ +5.01% +8.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers